Why carry out this study?

Heavily treatment-experienced (HTE) individuals with HIV-1 have limited therapeutic options, and new antiretroviral drug classes are needed for this population.

Efficacy and safety of fostemsavir + optimized background therapy (OBT) have previously been evaluated through 96 weeks; here, we report long-term efficacy and safety of fostemsavir + OBT in HTE adults with multidrug-resistant HIV-1 from the phase 3 BRIGHTE trial.

What was learned from this study?

A population with advanced disease and multidrug-resistant HIV-1 was able to achieve durable virologic responses and clinically meaningful improvements in CD4+ T-cell count and CD4+/CD8+ ratio on treatment with fostemsavir + OBT.

The safety and tolerability profile of fostemsavir + OBT remained consistent with prior observations through 96 weeks, with no new safety trends.

Long-term results provide further support for fostemsavir as a key therapeutic option for HTE people with multidrug-resistant HIV-1.